Antibody Engineering for Optimized Immunotherapy in Alzheimer's Disease
There are nearly 50 million people with Alzheimer's disease (AD) worldwide and currently no disease modifying treatment is available. AD is characterized by deposits of Amyloid-β (Aβ), neurofibrillary tangles, and neuroinflammation, and several drug discovery programmes studies have focussed on...
Main Authors: | Isabelle L. Sumner, Ross A. Edwards, Ayodeji A. Asuni, Jessica L. Teeling |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2018-04-01
|
Series: | Frontiers in Neuroscience |
Subjects: | |
Online Access: | http://journal.frontiersin.org/article/10.3389/fnins.2018.00254/full |
Similar Items
-
Application of Antibody Fragments Against Aβ With Emphasis on Combined Application With Nanoparticles in Alzheimer’s Disease
by: Zhi-Ting Sun, et al.
Published: (2021-04-01) -
Alzheimer’s disease and immunotherapy: what is wrong with clinical trials?
by: Kohyama K, et al.
Published: (2015-01-01) -
NEW ROLES FOR FC RECEPTORS IN NEURODEGENERATION-THE IMPACT ON IMMUNOTHERAPY FOR ALZHEIMER’S DISEASE
by: James P. Fuller, et al.
Published: (2014-08-01) -
Immunotherapy for the treatment of Alzheimer's disease: amyloid-β or tau, which is the right target?
by: Castillo-Carranza DL, et al.
Published: (2013-12-01) -
SPECT imaging of distribution and retention of a brain-penetrating bispecific amyloid-β antibody in a mouse model of Alzheimer’s disease
by: Tobias Gustavsson, et al.
Published: (2020-09-01)